FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022705162> ?p ?o ?g. }

• W2022705162 endingPage "23" @default.
• W2022705162 startingPage "18" @default.
• W2022705162 abstract "In bone metastases, the disruption of normal bone processes results in increased resorption and formation rates, which can often be quantitatively measured by biomarkers in the urine and blood. The purpose of this review is to summarize relevant studies of urinary markers used as a diagnostic and/or prognostic tool, as well as its potential and advances in directing therapy.A literature search was conducted using Ovid MEDLINE (1950 to July 2014), EMBASE (1950 to 2014 week 30) and Cochrane Central Register of Controlled Trials (3rd Quarter 2014) to identify studies that detailed the use of urinary markers in the cancer setting, specifically involving markers for bone metastases. Search terms included urinary markers, cancer, and bone metastases.A total of 35 articles, with 24 original studies, were identified. In general, urinary markers can be used to detect early signs of bone metastases prior to skeletal imaging, but still must be used in conjunction with imaging to avoid false positive results. The use of urinary markers, such as N-telopeptide, as a prognostic tool remains controversial, but can provide information on the relative risk of skeletal related events (SREs), disease progression, as well as death. Finally, while urinary markers have shown to be potentially useful in confirming the efficacy of bone metastases treatments, exploring the appropriate dosages for treatment, and directing therapy, it is still unclear to what extent urinary markers should be reduced by.The potential use of urinary markers in the management of bone metastases is promising as it can allow for earlier and more convenient detection of bone metastases in comparison to other techniques. However, additional studies involving prospective clinical trials are suggested to further examine the potential of urinary markers in developing appropriate treatment strategies and endpoints, especially in developing a clearer protocol on the extent urinary markers should be reduced by to correlate with achievement of clinical benefit." @default.
• W2022705162 created "2016-06-24" @default.
• W2022705162 creator A5003945533 @default.
• W2022705162 creator A5016605434 @default.
• W2022705162 creator A5018877755 @default.
• W2022705162 creator A5023362317 @default.
• W2022705162 creator A5034842369 @default.
• W2022705162 creator A5037349064 @default.
• W2022705162 creator A5047114036 @default.
• W2022705162 creator A5049539060 @default.
• W2022705162 creator A5054499982 @default.
• W2022705162 creator A5077301363 @default.
• W2022705162 date "2015-03-01" @default.
• W2022705162 modified "2023-09-26" @default.
• W2022705162 title "Use of urinary markers in cancer setting: A literature review" @default.
• W2022705162 cites W1517801548 @default.
• W2022705162 cites W1969503790 @default.
• W2022705162 cites W1971432874 @default.
• W2022705162 cites W1976822899 @default.
• W2022705162 cites W1979903598 @default.
• W2022705162 cites W1994476437 @default.
• W2022705162 cites W2004276150 @default.
• W2022705162 cites W2033712867 @default.
• W2022705162 cites W2038159208 @default.
• W2022705162 cites W2046750802 @default.
• W2022705162 cites W2048351536 @default.
• W2022705162 cites W2060700125 @default.
• W2022705162 cites W2064727215 @default.
• W2022705162 cites W2074757247 @default.
• W2022705162 cites W2082107301 @default.
• W2022705162 cites W2086556166 @default.
• W2022705162 cites W2094763732 @default.
• W2022705162 cites W2095170176 @default.
• W2022705162 cites W2113701976 @default.
• W2022705162 cites W2115962082 @default.
• W2022705162 cites W2120747154 @default.
• W2022705162 cites W2137654510 @default.
• W2022705162 cites W2145667356 @default.
• W2022705162 cites W2156893310 @default.
• W2022705162 cites W2159532621 @default.
• W2022705162 cites W2159646703 @default.
• W2022705162 cites W2162827359 @default.
• W2022705162 cites W2167574127 @default.
• W2022705162 cites W2267145211 @default.
• W2022705162 cites W2288888750 @default.
• W2022705162 cites W2401212195 @default.
• W2022705162 cites W2462936086 @default.
• W2022705162 cites W4231259650 @default.
• W2022705162 cites W4251017969 @default.
• W2022705162 doi "https://doi.org/10.1016/j.jbo.2015.01.002" @default.
• W2022705162 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4620969" @default.
• W2022705162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26579485" @default.
• W2022705162 hasPublicationYear "2015" @default.
• W2022705162 type Work @default.
• W2022705162 sameAs 2022705162 @default.
• W2022705162 citedByCount "4" @default.
• W2022705162 countsByYear W20227051622017 @default.
• W2022705162 countsByYear W20227051622018 @default.
• W2022705162 countsByYear W20227051622019 @default.
• W2022705162 countsByYear W20227051622021 @default.
• W2022705162 crossrefType "journal-article" @default.
• W2022705162 hasAuthorship W2022705162A5003945533 @default.
• W2022705162 hasAuthorship W2022705162A5016605434 @default.
• W2022705162 hasAuthorship W2022705162A5018877755 @default.
• W2022705162 hasAuthorship W2022705162A5023362317 @default.
• W2022705162 hasAuthorship W2022705162A5034842369 @default.
• W2022705162 hasAuthorship W2022705162A5037349064 @default.
• W2022705162 hasAuthorship W2022705162A5047114036 @default.
• W2022705162 hasAuthorship W2022705162A5049539060 @default.
• W2022705162 hasAuthorship W2022705162A5054499982 @default.
• W2022705162 hasAuthorship W2022705162A5077301363 @default.
• W2022705162 hasBestOaLocation W20227051621 @default.
• W2022705162 hasConcept C121608353 @default.
• W2022705162 hasConcept C126322002 @default.
• W2022705162 hasConcept C143998085 @default.
• W2022705162 hasConcept C2777783956 @default.
• W2022705162 hasConcept C2779013556 @default.
• W2022705162 hasConcept C673006 @default.
• W2022705162 hasConcept C71924100 @default.
• W2022705162 hasConcept C77411442 @default.
• W2022705162 hasConceptScore W2022705162C121608353 @default.
• W2022705162 hasConceptScore W2022705162C126322002 @default.
• W2022705162 hasConceptScore W2022705162C143998085 @default.
• W2022705162 hasConceptScore W2022705162C2777783956 @default.
• W2022705162 hasConceptScore W2022705162C2779013556 @default.
• W2022705162 hasConceptScore W2022705162C673006 @default.
• W2022705162 hasConceptScore W2022705162C71924100 @default.
• W2022705162 hasConceptScore W2022705162C77411442 @default.
• W2022705162 hasFunder F4320313339 @default.
• W2022705162 hasFunder F4320314085 @default.
• W2022705162 hasIssue "1" @default.
• W2022705162 hasLocation W20227051621 @default.
• W2022705162 hasLocation W20227051622 @default.
• W2022705162 hasLocation W20227051623 @default.
• W2022705162 hasLocation W20227051624 @default.
• W2022705162 hasLocation W20227051625 @default.
• W2022705162 hasOpenAccess W2022705162 @default.
• W2022705162 hasPrimaryLocation W20227051621 @default.

• next